Last updated on September 2017

A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND# 69896, NSC# 724772) for Patients with High Allelic Ratio FLT3 ITD


Other Details:

For more information, please contact:
844.229.3710
646.776.7532 (local)
Bayer@emergingmed.com

For Study Locations, Click Here



Find a site near you

Start Over

Research Center

Located in: Additional Locations, UT USA
  Connect »